A Study of Subcutaneous Delivery of JNJ-54767414 in Chinese Participants With Multiple Myeloma
Status:
Active, not recruiting
Trial end date:
2025-10-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety and pharmacokinetic of Daratumumab
subcutaneously in Chinese participants with relapsed or refractory Multiple Myeloma.